Sinobiomed announced its China subsidiary received a government subsidy of 9 million RMB ($1.24 million) to continue development of its malaria vaccine. According to Sinobiomed, the grant is the largest ever bestowed on a China biopharma. Sinobiomed’s 82% owned subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co. Ltd., is developing the vaccine in partnership with the Second Military Medical University. We look at the company, its finances and pipeline.  More details...

Stock Symbol: (OTCBB: SOBM)